Treatment of Limited Cutaneous Systemic Sclerosis with Gastro-Oesophageal Reflux Disease
Gastro-oesophageal reflux disease (GERD) is a recognised comorbidity in limited cutaneous systemic sclerosis (lcSSc). Its presence calls for a targeted treatment approach alongside management of the underlying connective tissue disease.
Clinical Scenario
This protocol addresses patients with limited cutaneous systemic sclerosis who have concurrent gastro-oesophageal reflux disease — a combination that carries risk of oesophageal complications including ulceration and stricture formation.
Treatment Approach (partial overview)
Management centres on a specific class of acid-suppressing therapy — the approach aims both to control reflux symptoms and to prevent oesophageal complications.
Full regimen, sequencing, and clinical guidance available via the protocol below →
References
DOI: 10.1136/ard-2024-226430
PPI should be considered for the treatment of SSc-GERD and prevention of oesophageal ulcers and strictures.
The task force acknowledged the need to address gastro-oesophageal reflux disease with PPI treatment at least in first instance and recommended their use in an attempt to control symptoms and prevent oesophageal complications.
View source ↗